Abstract:Topoisomerase II is a key target for several anti-cancer drugs used for breast cancer therapy, including doxorubicin, epirubicin and mitoxantrone. Two isoforms of topoisomerase II (alpha and beta) have been described in human cells which differ in their subcellular localisation, biochemical properties and susceptibility to inhibition by anti-cancer drugs. The relative level of expression of the alpha and beta isoforms may contribute to the degree of tumour responsiveness to different chemotherapeutic agents. To assess the relationship between expression of topoisomerase II isoforms and established prognostic factors and pathological variables, 56 primary breast tumour samples were studied. The expression of the two topoisomerase II genes was apparently not co-ordinately regulated in these tissue samples. There was no relationship between any of the commonly used pathological variables [tumour size, lymph node status, S-phase fraction (SPF)] and the level of expression of topoisomerase II beta mRNA. However, high topoisomerase II alpha gene expression was significantly associated with a high SPF (sign-rank test; P = 0.01). Moreover, the ratio of mRNA levels for topoisomerase II alpha and beta showed a stronger relationship to SPF (median raito 0.62 for tumours with SPF < 10, and 1.64 for SPF > 10; P = 0.0021, sign-rank test). As expected from previous studies, an SPF > 10 was associated with poor overall survival (P = 0.01). Immunohistochemical analysis revealed that topoisomerase II beta was widely distributed ( > 90% positive tumour cells), but that topoisomerase II alpha expression was less widely expressed, with a pattern of expression similar to that of the proliferation-dependent antigen recognised by Ki67. Because topoisomerase II gene expression showed a log-normal distribution, log-transformed data were used in multivariate analysis of relapse-free survival. This showed that lymph node status and topoisomerase II beta mRNA expression were the only significant survival factors (P = 0.001 and 0.05, respectively, with relative risks of 1.3 and 1.8). These results indicate that topoisomerase II alpha, but not beta, expression is dependent upon cellular proliferation status, but that the more widely expressed topoisomerase II beta protein may play a significant role as a target for anti-tumour therapy.

Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant.

Nuclear Topoisomerase II Levels Correlate with the Sensitivity of Mammalian Cells to Intercalating Agents and Epipodophyllotoxins.

Isolation and Partial Characterisation of a Mammalian Cell Mutant Hypersensitive to Topoisomerase II Inhibitors and X-rays.

Human cells (normal and ataxia telangiectasia) transfected with pR plasmid are hypersensitive to DNA strand-breaking agents

Cross-sensitivity to Topoisomerase II Inhibitors in Cytotoxic Drug-Hypersensitive Chinese Hamster Ovary Cell Lines.

Attenuation of Drug-Stimulated Topoisomerase Ii Dna Cleavable Complex Formation in Wild-Type Hl-60 Cells Treated with an Intracellular Calcium Buffer is Correlated with Decreased Cytotoxicity and Site-Specific Hypophosphorylation of Topoisomerase Ii Alpha

Isolation of Two Chinese Hamster Ovary Cell Mutants Hypersensitive to Topoisomerase II Inhibitors and Cross-Resistant to Peroxides.

Relationship Between Topoisomerase-Ii Level And Chemosensitivity In Human Tumor-Cell Lines

Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.

Overexpression of the RI Alpha Subunit of Protein Kinase A Confers Hypersensitivity to Topoisomerase II Inhibitors and 8-Chloro-cyclic Adenosine 3'5'-Monophosphate in Chinese Hamster Ovary Cells.

Altered Drug Interaction and Regulation of Topoisomerase IIbeta: Potential Mechanisms Governing Sensitivity of HL-60 Cells to Amsacrine and Etoposide.

Chemosensitivity in Human Tumor Cell Lines Relationship between Topoisomerase II Level and Updated Version

Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.

Relationship Between Expression of Topoisomerase II Isoforms and Intrinsic Sensitivity to Topoisomerase II Inhibitors in Breast Cancer Cell Lines

Cellular and molecular studies on ataxia-telangiectasia lymphoblastoid cell lines

Effect of ATM on telomerase activity in AT cells exposed to ionizing radiation

The Distribution and Expression of the Two Isoforms of DNA Topoisomerase II in Normal and Neoplastic Human Tissues.

Phosphorylation of Serine 1106 in the Catalytic Domain of Topoisomerase IIα Regulates Enzymatic Activity and Drug Sensitivity

Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.

Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations

Differential Expression of the Topoisomerase IIα and Β Genes in Human Breast Cancers